Quad elvitegravir/cobicistat/emtricitabine/tenofovir: Additional Phase II data

Additional data from an ongoing, double-blind Phase II trial (GS-US-236-0104) in 71 treatment-naïve patients with HIV RNA levels >=5,000 copies/mL showed that the proportion of patients who achieved HIV RNA levels <50 copies/mL at 24 weeks was 90% for the once-daily Quad arm vs. 83% for the Atripla emtricitabine/tenofovir/efavirenz arm. Data were presented at the Retroviruses and Opportunistic Infections meeting in San Francisco. Gilead previously reported that the Quad regimen was non-inferior to Atripla on the primary endpoint of the proportion of patients achieving HIV RNA levels <50 copies/mL at 24 weeks (see BioCentury, Jan. 11). ...